News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,232 Results
Type
Article (2439)
Company Profile (39)
Press Release (35754)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (14119)
Career Advice (77)
Deals (2078)
Drug Delivery (9)
Drug Development (4100)
Employer Resources (10)
FDA (431)
Job Trends (763)
News (20134)
Policy (1052)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (144)
Allergies (6)
Alliances (3473)
ALS (4)
Alzheimer's disease (46)
Antibody-drug conjugate (ADC) (16)
Approvals (432)
Artificial intelligence (11)
Autoimmune disease (3)
Automation (1)
Bankruptcy (12)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (29)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (20)
Cancer (144)
Cardiovascular disease (5)
Career advice (64)
Career pathing (1)
CAR-T (15)
Cell therapy (44)
Cervical cancer (2)
Clinical research (3180)
Collaboration (94)
Compensation (49)
COVID-19 (180)
CRISPR (7)
C-suite (30)
Cystic fibrosis (2)
Data (114)
Denatured (3)
Depression (3)
Diabetes (10)
Diagnostics (465)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (15)
Drug pricing (7)
Duchenne muscular dystrophy (12)
Earnings (4241)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6039)
Executive appointments (96)
FDA (478)
Featured Employer (3)
Funding (79)
Gene editing (14)
Gene therapy (18)
GLP-1 (60)
Government (149)
Healthcare (704)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (16)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (989)
IRA (7)
Job creations (290)
Job search strategy (62)
Kidney cancer (4)
Labor market (4)
Layoffs (37)
Leadership (1)
Legal (212)
Liver cancer (5)
Lung cancer (15)
Lymphoma (4)
Management (4)
Manufacturing (19)
MASH (4)
Medical device (307)
Medtech (307)
Mergers & acquisitions (1159)
Metabolic disorders (34)
Multiple sclerosis (8)
Neurodegenerative disease (9)
Neuropsychiatric disorders (3)
Neuroscience (92)
NextGen: Class of 2025 (352)
Non-profit (153)
Northern California (367)
Now hiring (4)
Obesity (16)
Opinion (15)
Ovarian cancer (10)
Pain (9)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (2)
Patents (23)
Patient recruitment (5)
Peanut (1)
People (5662)
Pharmaceutical (5)
Phase I (1374)
Phase II (1595)
Phase III (846)
Pipeline (77)
Policy (12)
Postmarket research (30)
Preclinical (593)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (22)
Real estate (420)
Recruiting (5)
Regulatory (805)
Reports (6)
Research institute (142)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (25)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (361)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (489)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1758)
Vaccines (28)
Venture capitalists (8)
Weight loss (12)
Women's health (1)
Worklife (1)
Date
Today (13)
Last 7 days (51)
Last 30 days (230)
Last 365 days (2542)
2025 (791)
2024 (2610)
2023 (2858)
2022 (3751)
2021 (4048)
2020 (3471)
2019 (2061)
2018 (1554)
2017 (1795)
2016 (1624)
2015 (1833)
2014 (1370)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (15)
Asia (1867)
Australia (298)
California (848)
Canada (134)
China (39)
Colorado (20)
Connecticut (10)
Delaware (4)
Europe (3823)
Florida (44)
Georgia (5)
Idaho (3)
Illinois (14)
India (1)
Indiana (33)
Japan (7)
Kansas (12)
Maryland (25)
Massachusetts (305)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (3)
New Hampshire (2)
New Jersey (70)
New York (49)
North Carolina (90)
Northern California (367)
Ohio (26)
Oklahoma (2)
Oregon (5)
Pennsylvania (50)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (361)
Tennessee (2)
Texas (72)
Utah (2)
Virginia (6)
Washington D.C. (1)
Washington State (52)
Wisconsin (6)
38,232 Results for "codiak biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process
Codiak BioSciences, Inc. today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company.
March 27, 2023
·
3 min read
Genetown
Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference
Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference.
November 28, 2022
·
1 min read
Business
Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring
Codiak BioSciences, Inc. announced a reprioritization of its clinical and research initiatives, an acceleration of discussions related to potential strategic corporate and program-based partnerships, and a restructuring of operations to support a streamlined set of priorities.
August 30, 2022
·
6 min read
Business
Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, reported third quarter 2022 financial results and recent operational progress.
November 3, 2022
·
8 min read
Biotech Bay
ATUM Announces Leap-In Transposase® Licensing Agreement with Codiak Biosciences to Support Manufacturing of Exosome-Based Therapeutics
ATUM, a global specialist and industry leader in bioengineering solutions, announced the signing of a full licensing agreement for the Leap-In Transposase® technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines.
January 24, 2023
·
3 min read
Genetown
Codiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor Conferences
Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in two upcoming investor conferences.
August 3, 2022
·
1 min read
Business
Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, reported second quarter 2022 financial results and recent operational progress.
August 4, 2022
·
9 min read
Business
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress
Codiak BioSciences, Inc. reported first quarter 2022 financial results and operational progress.
May 5, 2022
·
8 min read
Business
CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine
CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences announced the latest funding award under CEPI’s US $200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 and other Betacoronaviruses.
July 5, 2022
·
7 min read
Genetown
Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022
Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be attending the William Blair Biotech Focus Conference 2022 in New York City.
July 11, 2022
·
2 min read
1 of 3,824
Next
